诚达药业股份有限公司 2024 年度独立董事述职报告 （俞毅） 本人作为诚达药业股份有限公司（以下简称"公司"）第五届董事会的独立 董事，2024年严格按照《中华人民共和国公司法》《上市公司独立董事管理办法》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 等相关法律法规和《诚达药业股份有限公司章程》《诚达药业股份有限公司独立 董事工作制度》等公司相关的规定和要求，谨慎、认真、勤勉、独立地履行职责， 积极出席相关会议，对相关事项发表了独立意见，维护公司整体利益和全体股东 的合法权益。现将2024年度任职期间内履职情况汇报如下： 一、独立董事的基本情况 俞毅先生，1965年出生，中国国籍，无境外永久居留权，硕士研究生学历。 曾任浙江工商大学经济学院讲师、副教授、荣盛石化股份有限公司独立董事、杭 州壹网壹创科技股份有限公司独立董事、浙江众成包装材料股份有限公司独立董 事、浙江网盛生意宝股份有限公司独立董事、江西星星科技股份有限公司独立董 事、浙江帅丰电器股份有限公司独立董事、杭州博可生物科技股份有限公司独立 董事、杭州青云新材料股份有限公司独立董事；现任公司独立董事、浙江工商大 学经济学院 ...

Financial Performance - The company's operating revenue for 2024 was ¥333,131,182.38, a decrease of 19.59% compared to ¥414,301,764.07 in 2023[22]. - The net profit attributable to shareholders for 2024 was -¥28,103,664.37, representing a decline of 130.89% from ¥90,980,328.72 in 2023[22]. - The cash flow from operating activities for 2024 was ¥28,648,375.78, down 85.08% from ¥192,072,387.64 in 2023[22]. - The basic earnings per share for 2024 was -¥0.1849, a drop of 131.44% from ¥0.5881 in 2023[22]. - The total assets at the end of 2024 were ¥2,436,460,004.08, a decrease of 0.77% from ¥2,455,325,018.15 at the end of 2023[22]. - The net assets attributable to shareholders at the end of 2024 were ¥2,143,050,905.40, down 5.89% from ¥2,277,123,782.24 at the end of 2023[22]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, with a figure of -¥57,671,784.99 for 2024 compared to ¥53,817,789.32 in 2023, a decrease of 207.16%[22]. - The company's total operating costs were 190.48 million yuan, down 19.50% year-on-year, aligning with the decrease in operating revenue[54]. - Management expenses rose by 17.71% to 104.00 million yuan, driven by increased environmental health fees and personnel costs, while sales expenses surged by 45.05% to 4.63 million yuan due to higher marketing expenditures[55]. - The company reported a total cash flow from operating activities of 28.65 million yuan, a substantial decline of 85.08% year-on-year, mainly due to increased cash payments for goods and services[55]. Market Overview - The global CDMO market size reached approximately $75 billion in 2023, with a projected CAGR of 13.60% to $133 billion by 2027[32]. - The outsourcing ratio of pharmaceutical R&D investment is expected to increase from 46.5% in 2022 to 55.0% in 2026 globally[32]. - The global L-carnitine market size was $203.4 million in 2022, expected to grow at a CAGR of 4.9% from 2023 to 2030[33]. - The stem cell market is anticipated to grow from $13.66 billion in 2023 to $15.05 billion in 2024, reaching $27.99 billion by 2030, with a CAGR of 10.79%[34]. - The export value of raw materials is projected to reach $42.98 billion in 2024, with a year-on-year growth of 5.1%[35]. Research and Development - The company invested R&D expenses of ¥93.71 million, accounting for 28.13% of revenue, a 241.20% increase year-on-year[40]. - The company has established several technology platforms for chiral synthesis and other advanced chemical processes, enhancing its competitive edge in the market[46]. - The company has successfully initiated four projects in the water-soluble small molecule amino acid separation and purification technology platform[70]. - The company has completed six projects in the chiral synthesis technology platform, enhancing its ability to synthesize chiral compounds[70]. - The transition metal catalysis technology platform has supported the development of over ten projects, improving efficiency in new drug development[70]. - The number of R&D personnel increased by 36.26% to 124 in 2024, with a notable rise in the number of PhD holders from 2 to 6[72]. Corporate Governance - The company has established a complete corporate governance structure, ensuring that independent directors account for more than one-third of the board members[125]. - The board of directors consists of 7 members, including 3 independent directors, and held 6 meetings in the reporting period[119]. - The supervisory board is composed of 3 members, with 2 being employee representatives, and held 6 meetings during the reporting period[120]. - The company has a diverse board with independent directors, enhancing objective decision-making[125]. - The company has a clear separation of duties among its functional departments, ensuring independent operations[125]. Environmental Compliance - The company has established a comprehensive compliance framework with environmental regulations[169]. - The company processed wastewater to meet the Class III standard of the "Comprehensive Wastewater Discharge Standard" (GB8978-1996) before discharging it into the Jiaxing municipal sewage treatment plant[171]. - The company generated 1,462.79 tons of general solid waste and 5,589.58 tons of hazardous waste, all disposed of by qualified third parties[171]. - The company implemented a multi-stage treatment process for exhaust gases, achieving compliance with the "Air Pollutant Emission Standards for the Pharmaceutical Industry" (DB33/310005-2021)[173]. - The company actively explores water resource recycling, including the recovery of steam condensate for heat recovery and the reuse of clean wastewater for cooling[172]. Shareholder Relations - The company implemented a cash dividend policy, distributing RMB 2.00 per 10 shares, totaling RMB 30,293,824.80, which represents 100% of the profit distribution[158][160]. - The company emphasizes the recruitment and development of high-level research talent, resulting in a significant increase in the number of R&D personnel[99]. - The company is focused on maintaining shareholder interests while adapting to market demands and project progress[94]. - The company has engaged in multiple investor communications to discuss business development, including the application of L-carnitine and project progress[113]. - The company is committed to transparency in its financial performance and has provided detailed updates on its investment projects and operational progress during investor meetings[114].

Financial Performance - The company's revenue for Q1 2025 was ¥76,307,845, a decrease of 24.37% compared to ¥100,889,692.80 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥1,399,981.98, representing a decline of 107.51% from a profit of ¥18,644,506 in the previous year[5] - Basic and diluted earnings per share were both -¥0.0092, down 107.57% from ¥0.1215 in the previous year[5] - Net profit for the current period is a loss of ¥1,332,581.61, compared to a profit of ¥18,726,286.19 in the previous period[21] Cash Flow - The net cash flow from operating activities was negative at ¥22,961,570.56, a decrease of 160.29% compared to ¥38,083,815.26 in the same period last year[5] - Cash received from sales and services decreased by 52.45% to ¥63,888,356.57 compared to the previous period[13] - Cash received from other operating activities decreased by 65.27% to ¥2,865,624.18, mainly due to reduced export tax rebates and government subsidies[13] - Cash inflow from operating activities totaled 66,754,011.42, down from 142,615,023.64 in the prior period[26] - Cash outflow from operating activities was 89,715,581.98, compared to 104,531,208.38 previously[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,389,449,308.22, a decrease of 1.93% from ¥2,436,460,004.08 at the end of the previous year[5] - Total liabilities decreased to ¥245,088,305.93 from ¥290,766,420.18, reflecting a reduction of 15.7%[20] - The company's total equity is reported at ¥2,144,361,002.29, down from ¥2,145,693,583.90 in the previous period[20] - The company has a total non-current asset of ¥980,292,139.87, down from ¥1,021,296,347.94 in the previous period[20] Operating Costs and Expenses - Total operating costs decreased to ¥80,611,623.48, down 9.4% from ¥88,945,893.49 in the previous period[21] - The company's management expenses increased by 62.43% to ¥30,808,110.88, primarily due to increased depreciation during the trial production period after project delivery[9] - Research and development expenses for the current period are ¥9,022,289.07, slightly down from ¥9,782,578.34 in the previous period[21] Cash and Investments - The company's cash and cash equivalents increased to ¥445,496,148.82 from ¥178,463,170.90[18] - The company's trading financial assets decreased to ¥645,132,195.37 from ¥957,652,020.32[18] - Cash paid for investments increased significantly by 1390.31% to ¥1,500,000,000.00, mainly due to increased purchases of financial products[13] - The company received cash from investment recovery totaling 1,838,022,696.25 during the current period[27] Government Support - The company received government subsidies amounting to ¥673,984.65 during the reporting period, which were closely related to its normal business operations[6]

诚达药业股份有限公司 董事会审计委员会对会计师事务所 2024 年度履职情况评估 及履行监督职责情况报告 根据《 中华人民共和国公司法》 中华人民共和国证券法》 上市公司治理 准则》 国有企业、上市公司选聘会计师事务所管理办法》 深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规和规范性 文件及《 诚达药业股份有限公司章程》的相关规定和要求，诚达药业股份有限公 司《 以下简称《 公司"）董事会审计委员会本着勤勉尽责的原则，恪尽职守，认 真履职。现将董事会审计委员会对众华会计师事务所 特殊普通合伙）(以下简 称 众华")2024 年度履职评估及履行监督职责的情况汇报如下： 一、2024 年年审会计师事务所基本情况 一）会计师事务所基本情况 传输、软件和信息技术服务业等。众华提供审计服务的上市公司中与公司同行业 客户共 3 家。 二）聘任会计师事务所履行的程序 1、基本信息 众华的前身是 1985 年成立的上海社科院会计师事务所，于 2013 年经财政部 等部门批准转制成为特殊普通合伙企业。众华注册地址为上海市嘉定工业区叶城 路 1630 号 5 幢 1088 室。众华自 199 ...

证券代码：301201 证券简称：诚达药业 公告编号：2025-015 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 诚达药业股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开了第 五届董事会第十二次会议审议通过了《关于公司及子公司 2025 年度向银行申请 综合授信额度的议案》，同意公司及子公司向银行申请不超过人民币 4 亿元的综 合授信额度。现将有关情况公告如下： 一、本次申请银行综合授信额度情况 为满足公司日常生产经营和业务发展的资金需求，公司及子公司拟向中国建 设银行股份有限公司浙江长三角一体化示范区支行、招商银行上海自贸试验区临 港新片区支行、浙商银行股份有限公司嘉兴分行、中国银行股份有限公司浙江长 三角一体化示范区支行、嘉兴银行股份有限公司长三角一体化示范区（浙江嘉善） 支行、中国民生银行股份有限公司嘉兴嘉善支行等商业银行申请不超过人民币 4 亿元的综合授信额度，综合授信内容包括但不限于流动资金贷款、开立承兑汇票、 开立信用证、票据贴现等综合授信业务。上述授信额度仅为公司拟申请的授信额 度，具体授信金额需根据公司实际资金需求， ...

一、2024 年度监事会工作情况 2024 年，监事会认真履行工作职责，审慎行使《公司章程》和股东大会赋予 的职权，共召开 6 次监事会会议，会议的通知、召开、表决程序符合《公司法》 《公司章程》的要求。会议的主要情况如下： 2024 年度监事会工作报告 2024 年度，诚达药业股份有限公司（以下简称"公司"）监事会全体成员秉 承对全体股东负责的原则，在董事会及各级领导的支持和配合下，严格按照《中 华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下 简称《证券法》）和《公司章程》《监事会议事规则》等法律法规及规章制度的规 定，认真履行法律法规所赋予的各项职权和义务，对公司经营决策程序、依法运 作情况、财务状况以及内部管理等方面进行了核查，对公司董事会和高级管理人 员履职情况的合法性及合规性进行监督，充分发挥监事会的监督作用，在促进公 司规范运作和健康发展方面起到了积极的作用，切实有效地维护了股东、公司和 员工的合法权益。现将公司监事会 2024 年度工作情况报告如下： 诚达药业股份有限公司 | 会议届次 | | | | 召开日期 | | | 会议决议 | | --- | --- | - ...

诚达药业股份有限公司 2024 年度内部控制评价报告 诚达药业股份有限公司全体股东： 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《企业内部 控制基本规范》、《企业内部控制评价指引》、《深圳证券交易所创业板股票上 市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等法律法规及相关文件的规定和要求，并结合诚达药业股份有限公司 （以下简称"公司"）各项规章制度，在内部控制日常监督和专项监督的基础上， 公司董事会对公司截至 2024 年 12 月 31 日（内部控制评价报告基准日）的内部 控制有效性进行了如下评价： 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相 ...

证券代码：301201 证券简称：诚达药业 公告编号：2025-012 诚达药业股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 诚达药业股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第五 届董事会第十二次会议，审议通过了《关于续聘会计师事务所的议案》，公司拟 续聘众华会计师事务所（特殊普通合伙）(以下简称"众华")为公司 2025 年度 财务报告及内部控制审计机构。本议案尚需提交公司股东大会审议。现将相关事 项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 按照相关法律法规的规定，众华会计师事务所（特殊普通合伙）购买职业保 险累计赔偿限额 20,000 万元，能够覆盖因审计失败导致的民事赔偿责任，符合 相关规定。 众华上年度（2024 年）上市公司审计客户数量 73 家，审计收费总额为人民 币 9,193.46 万元。众华提供服务的上市公司中主要行业为制造业，房地产业、 信息传输、软件和信息技术服务业等。众华提供审计服务的上市公司中与公司同 行业客户共 3 家。 4、投资者保护能力 ...

经核查独立董事汪萍女士、俞毅先生、崔孙良先生的任职经历以及签署的相 关自查文件，上述人员未在公司担任除独立董事以外的任何职务，其配偶、父母、 子女、主要社会关系也未在公司任职，也未在公司主要股东公司担任任何职务， 与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断 的关系。因此，公司独立董事符合 上市公司独立董事管理办法》 深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》中对独立董事 独立性的相关要求。 诚达药业股份有限公司董事会 2025 年 4 月 23 日 诚达药业股份有限公司 董事会关于独立董事独立性自查情况的专项意见 根据《 中华人民共和国公司法》 上市公司独立董事管理办法》 深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规和 规范性文件及《 诚达药业股份有限公司章程》的相关规定，诚达药业股份有限公 司《 以下简称《 公司"）就 2024 年度在任独立董事汪萍女士、俞毅先生、崔孙良 先生提交的 2024 年度独立董事独立性自查情况报告》进行评估并出具如下专 项意见： ...

证券代码：301201 证券简称：诚达药业 公告编号：2025-017 诚达药业股份有限公司 备金额为 778.87 万元；计提的合同资产减值损失为 5.31 万元。 根据《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》等相关法律法规以及《公司章程》等相关规定，本次计提及转回资产减 值准备无需提交公司董事会或股东大会审议。 2、本次计提及转回资产减值准备的情况 单位：万元 | 项 目 | 本期计提 | 本期转回或 | 本期影响损益金额（ | | --- | --- | --- | --- | | | | 转销 | 收益以"-"号填列） | | 一、资产减值损失 | 784.18 | 0.00 | 784.18 | | 其中：存货跌价准备 | 778.87 | 0.00 | 778.87 | | 合同资产减值损失 | 5.31 | 0.00 | 5.31 | | 二、信用减值损失计提 | -176.16 | 299.43 | -475.59 | | 其中：应收账款坏账准备 | -176.22 | 0.00 | -176.22 | | 其他应收款坏账准备 | 0.06 | 299.43 | ...